ProCE Banner Activity

Current Therapeutic Strategies for Newly Diagnosed MM That Are Eligible for ASCT

Slideset Download
Download this slideset based on the content from the annual CCO/IMF satellite symposium at ASH on selecting optimal therapy for patients with newly diagnosed multiple myeloma who are eligible for ASCT.

Released: December 15, 2021

Expiration: December 14, 2022

No longer available for credit.
Begin Activity

Share

Faculty

Philippe Moreau

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Pfizer, Inc.

Sanofi Genzyme

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France